• Skip to primary navigation
  • Skip to main content
SRI logo
  • About
    • Press room
    • Our history
  • Expertise
    • Advanced imaging systems
    • Artificial intelligence
    • Biomedical R&D services
    • Biomedical sciences
    • Computer vision
    • Cyber & formal methods
    • Education and learning
    • Innovation strategy and policy
    • National security
    • Ocean & space
    • Quantum
    • Robotics, sensors & devices
    • Speech & natural language
    • Video test & measurement
  • Ventures
  • NSIC
  • Careers
  • Contact
  • 日本支社
Search
Close
Biomedical sciences publications November 1, 2013

AT-202, a Nociceptin Receptor Agonist, Blocks Drug- and Stress-Induced Reinstatement of Extinguished Cocaine Conditioned Place Preference

Citation

Copy to clipboard


Khroyan, T. V., Polgar, W., Toll, L., Jiang, F., & Zaveri, N. T. (2013, 9-13 November). AT-202, a nociceptin receptor agonist, blocks drug- and stress-induced reinstatement of extinguished cocaine conditioned place preference. Paper presented at the Neuroscience 2013, San Diego, CA.

Abstract

Central administration of nociceptin/orphanin FQ (N/OFQ), the endogenous agonist peptide ligand for the nociceptin (NOP) receptor, has been shown to block conditioned place preference (CPP) of a variety of abused drugs, including psychostimulants such as cocaine and amphetamine. However, small-molecule NOP agonists have not been extensively examined for their effects on acquisition and reinstatement of psychostimulant CPP. We have previously shown that a small-molecule NOP agonist AT-202 (formerly SR16835) attenuates acquisition of morphine CPP. In the present study we examined the effects of AT-202 on acquisition and drug-primed or stress-induced reinstatement of cocaine CPP. To establish CPP, testing was conducted over six consecutive days resulting in three drug and three vehicle pairing sessions. To assess the effects on drug reinstatement following the first CPP test, separate groups of animals underwent daily extinction sessions during which animals were exposed to both compartments for 15 min. When animals had satisfied the extinction criterion, they were tested for reinstatement of extinguished cocaine CPP. Cocaine at doses of 5-30 mg/kg, produced robust CPP. Following acquisition of cocaine CPP and subsequent extinction, a cocaine prime reinstated extinguished drug seeking similar to the levels observed during the first CPP test. AT-202 pretreatment prior to the lowest dose of cocaine (5 mg/kg) did not alter the acquisition of cocaine CPP. We further established that AT-202 alone did not reinstate extinguished cocaine CPP. Notably, however, AT-202 blocked reinstatement of cocaine CPP when given as a pretreatment prior to a priming injection of cocaine. We also examined the effects of AT-202 on stress-induced reinstatement of extinguished cocaine CPP, using forced swim and a chemical stressor, yohimbine, to induce stress. Both forced swim and yohimbine (2 mg/kg) reinstate extinguished cocaine CPP to similar levels obtained during the first CPP test. AT-202 given as a pretreatment to forced swim and yohimbine, blocked reinstatement of extinguished cocaine CPP. These results show that even though AT-202 does not block acquisition of cocaine CPP, it is able to block reinstatement of both ‘drug-primed’ and ‘stress-induced’ cocaine CPP. These findings provide preliminary evidence that the NOP receptor agonists may be useful as pharmacotherapies to treat psychostimulant addiction and may be especially valuable in relapse prevention.

↓ View online

Share this
Career call to action image

Work with us

Search jobs

How can we help?

Once you hit send…

We’ll match your inquiry to the person who can best help you.

Expect a response within 48 hours.

Our work

Case studies

Publications

Timeline of innovation

Areas of expertise

Institute

Leadership

Press room

Media inquiries

Compliance

Careers

Job listings

Contact

SRI Ventures

Our locations

Headquarters

333 Ravenswood Ave
Menlo Park, CA 94025 USA

+1 (650) 859-2000

Subscribe to our newsletter


日本支社
SRI International
  • Contact us
  • Privacy Policy
  • Cookies
  • DMCA
  • Copyright © 2023 SRI International
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}